A Minnesota jury awarded $65.5 million on Friday to a mother of three who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing cancer in the lining of her lungs.Jurors determined that plaintiff Anna Jean Houghton Carley, 37, should be compensated by Johnson & Johnson after using its baby powder throughout her childhood and later developing mesothelioma, an aggressive cancer caused primarily by exposure to the carcinogen asbestos.Johnson & Johnson said i ...

The middle class trades time for money while the wealthy build systems that generate income around the clock. This fundamental difference explains why some people work their entire lives without accumulating significant wealth, while others achieve financial independence within a decade or two.Passive income isn’t about get-rich-quick schemes. It’s about putting your capital and knowledge to work in ways that compound over time without requiring your constant attention.The five strategies below represent pr ...

事件概述 - 美国总统特朗普预计于周五宣布旨在降低处方药价格的新协议 公告定于美国东部时间下午1点在白宫举行 [1][5] - 艾伯维、百时美施贵宝、吉利德科学和默克等主要制药商预计将宣布降低部分药品价格的协议 [1][5] - 瑞士制药商诺华和罗氏预计也将参与 [5] 政策背景与公司参与情况 - 特朗普于7月向17家主要制药公司领导人致信 概述了它们应如何向美国政府针对低收入人群的医疗补助计划提供所谓的最惠国价格 并保证新药定价不高于其他高收入国家 [2][5] - 截至目前已有五家公司与政府达成控制价格的协议 它们是辉瑞、礼来、阿斯利康、诺和诺德以及德国默克集团的美国分部EMD Serono [5] - 其余12家公司为赛诺菲、再生元、默克、强生、艾伯维、安进、吉利德、勃林格殷格翰、百时美施贵宝、葛兰素史克、诺华以及罗氏的美国子公司基因泰克 [5] - 百时美施贵宝、吉利德和白宫未立即回应置评请求 艾伯维和默克拒绝置评 [5] - 诺华表示正在与特朗普政府进行讨论 并致力于寻找降低美国人成本的解决方案 罗氏表示支持特朗普降低药品成本的目标 并鼓励其他国家奖励生物制药创新 [5] 市场影响与分析 - 特朗普长期关注美国与其他富裕国家之间的药价差异 后者拥有可协商价格折扣的政府运营医疗系统 [5] - 美国政府加强价格控制的前景最初吓坏了投资者 但迄今为止宣布的交易条款缓解了许多此类担忧 [5] - 分析师指出 医疗补助计划仅占美国药品支出的约10% 并且已经享有大幅价格折扣 在某些情况下超过80% [5][6] - 辉瑞在周二宣布其2026年财务展望时表示 医疗补助折扣将在明年导致价格和利润率受到挤压 [5][6]

High Income DIY Portfolios: The primary goal of "High Income DIY Portfolios" Marketplace service is high income with low risk and preservation of capital. It provides DIY investors with vital information and portfolio/asset allocation strategies to help create stable, long-term passive income with sustainable yields. The portfolios are designed for Income-Investors (including retirees or near-retirees). We provide seven portfolios: 3 buy-and-hold, 3 Rotational portfolios, and 3-Bucket NPP Model Portfolio. T ...

By signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox. ...

President Donald Trump on Friday unveiled a sweeping set of drug-pricing agreements with nine major pharmaceutical companies, presenting the initiative as a cornerstone of his effort to bring American medicine costs closer to those paid in Europe.The announcement marked a significant expansion of the administration’s pricing push, with Trump confirming that deals have now been struck with 14 of the 17 drugmakers he formally pressed in July to lower prices. Central to the strategy is the launch of a new dire ...

案件核心判决 - 明尼苏达州陪审团裁定强生公司向一名37岁的三孩母亲支付6550万美元赔偿金 因其滑石粉产品使其接触石棉并导致间皮瘤 [1] - 该判决为明尼苏达州历史上最大的石棉相关案件裁决 [5] - 整个判决属于补偿性质 包括对过去和未来的经济及非经济损失的赔偿 [5] 案件背景与指控 - 原告安娜·琼·霍顿·卡利于2025年被诊断出间皮瘤 这是一种仅由接触石棉引起的绝症 [3] - 原告童年时期持续使用强生婴儿爽身粉 而使用该产品的人从未被告知其危险 [3] - 强生公司在美国市场于2020年下架了该产品 [3] - 陪审团听取了证据 表明强生公司在明知滑石粉可能被致癌物石棉污染的情况下 仍销售和营销其滑石粉消费品 [2] - 原告律师团队向陪审团提供的证据显示 强生公司数十年来已知滑石矿常与石棉伴生 且内部测试和外部科学文献均对污染提出担忧 但公司仍继续宣传其产品可安全日常使用 [4] 法律诉讼与历史案例 - 此次判决源于拉姆齐县地方法院为期13天的审判 [2] - 原告律师表示 此案不仅关乎赔偿 更关乎真相和问责 [4] - 2025年 原告代理律所及其律师在全国范围内赢得了多项判决 包括一起加利福尼亚州案件 陪审团裁定强生公司向其客户支付近10亿美元赔偿 据信这是与强生滑石粉产品相关的间皮瘤案件中最大的判决 [6]

Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer talked about recently. Cramer mentioned the stock during the episode and said: “These groups were the salvation of this market when the year of magical investing ended, and the super speculative stocks started coming back to earth, they’re still doing it, followed by the data center plays. These were the groups that saved you. We don’t talk about this migration much, but all you need to know is just to look at the stocks of Merck and Johnson & J ...

Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government’s Medicaid program and for cash payers, in his latest bid to align US costs with those in other wealthy nations.Bristol Myers Squibb, Gilead Sciences, and Merck and Roche’s US unit Genentech have struck deals. Novartis, Amgen, Boehringer Ingelheim, Sanofi and GSK have also signed on.Under the deals, each drugmaker will cut prices on most drugs sold to the Medicaid p ...

US President Donald Trump on Friday (December 19) announced agreements with nine major pharmaceutical companies to sharply cut the prices of medicines sold through the government’s Medicaid program and to cash-paying consumers, marking his latest push to bring US drug costs in line with those in other wealthy nations.The deals were unveiled at a White House press conference, where Trump appeared alongside senior executives from the participating drugmakers.“We were subsidizing the entire world. We’re not do ...